Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.001 Par Value
-
Shares outstanding
-
13.1M
-
Number of holders
-
33
-
Total 13F shares, excl. options
-
8.26M
-
Shares change
-
+725K
-
Total reported value, excl. options
-
$66.1M
-
Value change
-
+$5.78M
-
Number of buys
-
15
-
Number of sells
-
-8
-
Price
-
$8.01
Significant Holders of Avalo Therapeutics, Inc. - Common Stock, $0.001 Par Value (AVTX) as of Q1 2025
37 filings reported holding AVTX - Avalo Therapeutics, Inc. - Common Stock, $0.001 Par Value as of Q1 2025.
Avalo Therapeutics, Inc. - Common Stock, $0.001 Par Value (AVTX) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.26M shares
of 13.1M outstanding shares and own 63.1% of the company stock.
Largest 10 shareholders include BVF INC/IL (1.04M shares), RA CAPITAL MANAGEMENT, L.P. (967K shares), ORBIMED ADVISORS LLC (967K shares), Nantahala Capital Management, LLC (900K shares), Deep Track Capital, LP (860K shares), Affinity Asset Advisors, LLC (657K shares), PERCEPTIVE ADVISORS LLC (520K shares), TCG Crossover Management, LLC (483K shares), COMMODORE CAPITAL LP (483K shares), and RWA WEALTH PARTNERS, LLC (313K shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.